Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

Purified Anti-Human CD134 Antibody[Ber-ACT35]

Product Sizes
25 ug
£99.00
E-AB-F1153A-25UG
100 ug
£169.00
E-AB-F1153A-100UG
1 mg
£405.00
E-AB-F1153A-1MG
5 mg
£1515.00
E-AB-F1153A-5MG
25 mg
£5832.00
E-AB-F1153A-25MG
50 mg
£10187.00
E-AB-F1153A-50MG
100 mg
£14542.00
E-AB-F1153A-100MG
About this Product
SKU:
E-AB-F1153A
Additional Names:
IMD;ACT;Tumor necrosis factor receptor superfamily member;Txgp;TNFRSF;TNFRSF4;ACT35;CD134;IMD16;OX40;TXGP1L;ACT35 antigen;OX40L receptor;Recombinant Human OX40/TNFRSF4 Protein (C-Fc);Recombinant Human OX40/TNFRSF4 Protein (C-Fc-Avi);Recombinant Human OX40/TNFRSF4 Protein (C-mFc);Recombinant Human OX40/TNFRSF4 Protein (N-Fc);Tumor necrosis factor receptor superfamily member 4;Txgp1;OX-40; TNFRSF4;Recombinant Human OX40/TNFRSF4 Protein (C-Fc);Recombinant Human OX40/TNFRSF4 Protein (N-Fc)
Application:
Flow Cytometry
Buffer:
PBS, pH 7.2. Contains 0.05% proclin 300.
translate.label.attr.clone:
Ber-ACT35
Clonality:
Monoclonal
Concentration:
>= 1 mg/ml
Extra Details:
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that this receptor promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. The knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell prolifeRation and differentiation.
Host:
Mouse
Immunogen:
CD134|Recombinant Human CD134 protein
Isotype:
IgG1, kappa
Purity:
>98%
Purification:
protein a/g purified
Reactivities:
Human
Shipping Conditions:
Blue Ice
Storage Conditions:
2-8[o]C Avoid freeze/thaw cycles., -20[o]C Avoid freeze/thaw cycles.
Supplier:
Elabscience
Type:
Antibody: Monoclonal Antibody
Human peripheral blood lymphocytes cell were stained with 0.2 ug AF/LE Purified Anti-Human CD200 Antibody[OX-104] (Right) and 0.2 ug Mouse IgG1, K Kappa Isotype Control (Left), followed by Elab Fluor® 647-conjugated Goat Anti-Mouse IgG Secondary Antibody, then anti-Human CD4 PE-conjugated Monoclonal Antibody.
Human peripheral blood monocytes cell were stained with 0.2 ug Purified Anti-Human CD36 Antibody[5-271] (Right) and 0.2 ug Mouse IgG2a, K Kappa Isotype Control (Left), followed by Elab Fluor® 647-conjugated Goat Anti-Mouse IgG Secondary Antibody.
Human peripheral blood lymphocytes cell were stained with 0.2 ug Purified Anti-Human CD200 Antibody[OX-104] (Right) and 0.2 ug Mouse IgG1, K Kappa Isotype Control (Left), followed by Elab Fluor® 647-conjugated Goat Anti-Mouse IgG Secondary Antibody, then anti-Human CD4 PE-conjugated Monoclonal Antibody.
Ht29 were stained with 0.2 ug Purified Anti-Human CD326 Antibody[9C4] (Right) and 0.2 ug Mouse IgG2b, K Kappa Isotype Control (Left), followed by Elab Fluor® 647-conjugated Goat Anti-Mouse IgG Secondary Antibody.
Human peripheral blood platelet were stained with 0.2 ug Purified Anti-Human CD61 Antibody[VI-PL2] (Right) and 0.2 ug Mouse IgG1, K Kappa Isotype Control (Left), followed by Elab Fluor® 647-conjugated Goat Anti-Mouse IgG Secondary Antibody.